# SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

> **NCT00871546** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** SCH 727965
- **DRUG:** Bortezomib
- **BIOLOGICAL:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00871546
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871546, "SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00871546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*